Abstract 29
The high mortality rate of hepatocellular carcinoma (HCC) is primarily due to its late diagnosis. In the 30 past numerous attempts have been made to design genetic biomarkers for the identification of HCC; 31 unfortunately, most of the studies are based on a small dataset obtained from a specific platform or 32 lack of their reasonable validation performance on the external datasets. In order to identify a universal 33 expression-based diagnostic biomarker panel for HCC that can be applicable across multiple platforms; 34 we have employed large scale transcriptomic profiling datasets containing a total of 2,306 HCC and 35 1,655 non-tumorous tissue samples. These samples were obtained from 29 studies generated by mainly 36 four types of profiling techniques include Affymetrix, Illumina, Agilent and High-throughput-seq, 37 which implemented a wide range of platforms. Firstly, we scrutinized 26 genes that are differentially 38 expressed or regulated in uniform pattern among numerous datasets. Subsequently, we identified three 39 genes (FCN3, CLEC1B, & PRC1) panel-based HCC biomarker using different machine learning 40 techniques include Simple-threshold based approach, Extra Trees, Support Vector Machine, Random 41
Forest, K Neighbors Classifier, Logistic Regression etc. Three-genes panel-based HCC biomarker 42 classified HCC samples and non-tumorous samples of training and three external validation datasets 43
with an accuracy between 93 to 98% and AUROC (Area Under Receiver Operating Characteristic 44 curve) in a range of 0.97 to 1.0. Furthermore, the prognostic potential of these genes was evaluated on 45 TCGA cohort and GSE14520 cohort using univariate survival analysis revealed that these genes are 46 independent prognostic indicators for various types of the survivals, i.e. OS (Overall Survival), PFS 47
(Progression-Free Survival), DFS/RFS (Disease-Free Survival/Recurrence-Free Survival) and DSS 48 (Disease-Specific Survival) of HCC patients and significantly stratify high-risk and low-risk HCC 49 patients (p-value <0.05). In conclusion, we identified a universal platform-independent three genes-50 based biomarker that can predict HCC patients with high precision; also possess significant prognostic Among the 22 common cancer type, Hepatocellular carcinoma (HCC) ranks at sixth in terms of 62 frequency of occurrence and fourth at cancer-related mortality (Siegel et al., 2019) . The aetiology of 63 HCC can be induced by multiple factors, especially virus infection, alcoholic cirrhosis and 64 consumption of aflatoxin-contaminated foods (Ho et al., 2016) . Although various traditional and 65 locoregional treatment strategies such as Hepatic resection (RES), Percutaneous ethanol injection 66 (PEI), radiofrequency ablation (RFA), microwave ablation (MWA) and trans-arterial chemotherapy 67 infusion (TACI) have improved the survival rate but patient with HCC still have a late diagnosis and 68 poor prognosis (Tian et al., 2018) . 69
In the past, several studies focus on the identification of biomarkers by comparing the global gene 70 expression changes between cancer tissue and non-tumorous tissues ( that play a crucial role in neoplastic transformation and progression (Rhodes et al., 2004) . The lack of 77 concordance of signature genes among different studies and extensive molecular variation between the 78 patient's samples restrains the establishment of the robust biomarkers, promising targets and their 79 experimental validation in clinical trials (Vasudevan et al., 2018) . The transcriptome signatures have 80 yet to be translated into a clinically useful biomarker, that may be due to a lack of their satisfactory 81 validation performance on independent patient's cohort. 82
In this regarding, treatment of HCC remains unsatisfying as only diagnostic and prognostic 83 biomarkers alpha-fetoprotein (AFP) has been established so far. Several other biomarkers AFP-L3, 84 osteopontin, glypican-3 are currently being under investigation for the early diagnosis of HCC patients 85 (Ocker, 2018 To overcome the limitations of existing methods, we made a systematic attempt to identify 98 genetic biomarkers for HCC diagnosis that apply to a wide range of platforms and profiling techniques. 99
One of the objectives of this study is to identify robust gene expression signature for discrimination of 100 HCC samples by the integration of multiple transcriptomic datasets from various platforms. Here, we 101 have collected and analysed a total of 3,961 samples from published datasets, out of which 2,306 and 102 1,655 are of HCC and normal or non-tumorous tissue samples, respectively. From this, we identified 103 26 genes, which are commonly differentially expressed in uniform patterns among most of the datasets, 104
which provides a universally activated transcriptional signature of HCC cancer type. Further, we have 105 established a robust "Three-genes based HCC biomarker" implementing different machine learning 106 techniques to distinguish HCC and non-tumorous samples with high precision. Additionally, the 107 survival analysis of HCC patient's cohorts using these genes revealed their significant prognostic 108 potential in the stratification of high-risk and low-risk patient's groups. To best of our knowledge, this 109
is the first study in the regards of HCC cancer type, which utilizes such a large-scale transcriptomic 110 dataset from different platforms, for the identification of universal platform-independent diagnostic 111 biomarkers implementing machine learning approaches. 112
Materials and Methods 113

2.1
Dataset Collection 114
Collection of gene expression datasets of HCC 115
In order to analyse the large-scale gene expression profiles in Hepatocellular carcinoma (HCC), 116 supplementary data for twenty-nine transcriptome studies (GSE102079 ( samples. All these datasets were initially obtained using GEOquery package (Bioconductor -127
GEOquery) from GEO and TCGA-LIHC RNA-seq data with metadata and clinical files was 128 downloaded using gdc-client from GDC data portal, respectively. Then, we manually curated these 129 datasets to ensure that the data contains only expression data from human HCC tissues. For each of the 130 29 datasets included in the current study, we reviewed the samples profiled. Twenty-nine studies had 131 at least ten samples corresponding to both classes, i.e. HCC and normal (or adjacent non-tumor) were 132 considered for the analysis of interest. Further, each dataset carefully investigated to check proper 133 sample ID, type of sample and to remove any irrelevant error in dataset file. Besides, Gene symbol 134 mapped to probe IDs were extracted from respective Platform file (wherever available) and 135 incorporated in the dataset matrix for each dataset. 136
Pre-processing of datasets 137
Each retrieved raw dataset (supplementary data) was subjected to a detailed curation process. 138 We have pre-processed each dataset matrix individually from each profiling technique for each 139 platform in a standardized manner. For Affymetrix datasets, raw data files were pre-processed with 140 background correction and eventually RMA values calculated using the Oligo package ( raw Agilent-1-color and Agilent-2-color files were pre-processed using Limma package individually, 144 then A-values were generated, which were further transformed to log2 values. Eventually, the average 145 of multiple probes computed that correspond to a single gene for each dataset individually employing 146 in-house R scripts. TCGA-LIHC dataset contains FPKM values, which were further converted to log2 147 values. Entrez transcript IDs are mapped to the Gene symbols using Gencode v22. 148
Datasets used for the Identification of Differentially Expressed Genes (DEG) 149
Twenty-five out of twenty-nine datasets selected, each containing samples more than ten for 150 initial analysis to identify differentially expressed genes between HCC and normal as given in Figure  151 1A. These datasets were further analyzed to assign the samples to three different classes, 
Training and Independent Validation Datasets 160
Four out of twenty-nine datasets (GSE25097, GSE14520, GSE36376 and TCGA-LIHC 161 datasets) selected each having more than 400 samples, for training the model and validation as given 162
in Figure 1B . To reduce the cross-platform artifacts, quantile normalization is performed using the 163 PreprocessCore package of Bioconductor (GitHub -bmbolstad/preprocessCore) for each dataset and 164 for each profiling technique by keeping training dataset as model (target) matrix. These datasets contain 165 a total of 1107 HCC and 706 adjacent non-tumor samples. 166
Analysis for the Identification of Differentially Expressed Genes (DEGs) 167
For each of the 32 microarray datasets, each gene was analyzed for differential expression with 168
Student's t-test (Welch t-test and Wilcoxon t-test) using in-house Rscript after the assignment of 169 samples to the respective class, i.e. cancer or normal. T-tests were conducted as two-sided for 170 differential expression analysis. Only those set of genes chosen to define differential expressed genes 171 from each of datasets that are statistically differentially expressed between two classes with Bonferroni 172 adjusted p-value less than 0.01. With aim to identify a selected set of differential expression signatures 173
or "core genes of Hepatocellular carcinoma", DEGs were compared among all 27 datasets. 174
Identification of Robust Biomarkers for HCC Diagnosis 175
Reduction of Features 176
With intent to reduce the number of genes from the selected the set of signature, i.e. "the core 177 genes of Hepatocellular carcinoma", we used two machine learning feature selection techniques 178 6 include simple threshold-based approach (Bhalla et al., 2017) and ten-fold cross-validation technique 179 using training cohort (GSE25097). Firstly, we employed a simple threshold-based technique in which 180
we developed single feature-based models to distinguish cancer and normal samples. Single feature-181 based models are also called threshold-based models wherein genes with a score above the threshold 182 are assigned to cancer class if it is found to be upregulated in cancer and otherwise normal; whereas 183 sample is assigned to normal class if the gene is downregulated in cancerous condition as reported in 184 our previous studies ( 
Performance Evaluation of Models 200
In the current study, both internal and external validation techniques were employed to evaluate 201 the performance of models. First, the training dataset is used to develop prediction models and ten-fold 202 cross-validation is used for performing internal validation. It is important to evaluate the 203 realistic performance of the model on external validation dataset, which should not be used for training 204 and testing during model development. Therefore, we also implemented external validation. Towards 205 this, we evaluated the performance of our model on three independent gene expression cohorts include 206 GSE14520, GSE36376, and TCGA-LIHC obtained from GEO and The Cancer Genome Atlas 207 (TCGA), each containing more than 400 samples (Supplementary Information File 2, Figure S1C ), 208
were not used for training. In order to measure the performance of models, we used standard 209
parameters. Both threshold-dependent and threshold-independent parameters were employed to 210 measure the performance. In the case of threshold-dependent parameters, we measure sensitivity, 211 specificity, accuracy and Matthew's correlation coefficient (MCC) using the following equations. 212
(2) 214
Where, FP, FN, TP and TN are false positive, false negative true positive and true negative predictions, 217 respectively. 218
While, for threshold-independent measures, we used a standard parameter Area under the Receiver 219
Operating Characteristic curve (AUROC). The AUROC curve is generated by plotting sensitivity or 220 true positive rate against the false positive rate (1-specificity) at various thresholds. Finally, the area 221 under the curve calculated to compute a single parameter called AUROC. 222
Prognostic Potential of Identified HCC Diagnostic Biomarkers 223
The prognostic potential of the "Three-genes HCC Biomarker" was analyzed using gene 224 expression data of TCGA-LIHC and GSE14520 cohorts. 
Functional Annotation of Signature Genomic Markers 235
In order to discern the biological relevance of the signature genes, enrichment analysis is 236 performed using Enrichr (Kuleshov et al., 2016) . Enrichr executes Fisher exact test to identify 237 enrichment score. It provides Z-score and adjusted p-value, which is derived by applying correction on 238 a Fisher Exact test. 239
3
Results 240
Overview 241
The pipeline of our analysis is illustrated in Figure 2 . The details of each step are described 242 below. 
The Transcriptomic Cores for Hepatocellular Carcinoma 247
The individual statistical differential expression analyses of 27 gene expression datasets resulted 248
in the identification of hundreds of upregulated and downregulated Differentially Expressed Genes 249 (DEGs) (Supplementary Figure 1 ). The 9,954 genes are present among each of 27 datasets 250 (Supplementary Information File 1, Table S1 ). Further, the comparative analysis among all 27 datasets 251 scrutinized 26 genes that are found to statistically differentially expressed in at least more than 80% of 252 the datasets, i.e. 22 datasets. We called these genes as "Core genes for Hepatocellular carcinoma". 253
Among these 26 genes, 12 are downregulated and 14 are upregulated in HCC in comparison to normal 254 samples. The regulatory patterns of the core genes were consistent among most of the datasets (Table  255 1). Additionally, the expression pattern of these genes in training and three external validation datasets 256 is shown in Figure S2 
.2 Gene Enrichment analysis of the Transcriptomic Cores for Hepatocellular Carcinoma 269
Gene enrichment analysis of these "core genes of HCC" revealed their biological significance 270 as the proteins encoded by the downregulated genes mainly enriched in complement activation and 271 lectin pathways related processes and negatively regulate cellular extravasation. They are also enriched 272 in GO molecular functions like serine-type endopeptidase activity, oxidoreductase activity, RNA 273 methyltransferase activity, etc. (Supplementary Information File 2, Figure S3 ). Whereas, upregulated 274 core genes enriched in cell cycle GO biological processes like mitotic spindle organization and mitotic 275 sister chromatid segregation, DNA synthesis and DNA replication, postreplication repair and cellular 276 Figure S3 ). 279
Identification of Robust HCC Biomarkers 280
With the aim to identify most important genes from the selected set of the signature, i.e. "the core genes 281 of Hepatocellular carcinoma", a simple threshold-based approach (Bhalla et al., 2017; Kaur et al., 282 2018) and ten-fold cross-validation technique employed using training dataset (GSE25097). 283
Single Gene Prediction Models using Simple Threshold-based Approach 284
Here, a simple threshold-based approach employed to distinguish cancer and normal samples. We 285 developed simple threshold-based models for each gene of "the core genes of Hepatocellular 286 carcinoma". Subsequently, all 26 genes are ranked based on their discriminatory power to distinguish 287 cancer from normal tissue samples as shown in table (Supplementary Information File 1, Table S2 ). 288
The top 10 genes among the core genes of HCC with the highest performance (i.e. Accuracy > 85%, 289 MCC >0.75 and AUROC >0.85) are selected and enlisted in Table 2 . 290 291 
Single Gene Prediction Models using Cross-validation Technique 297
We have obtained the top 10 genes to classify HCC and normal samples based on simple threshold-298 based approach. Further, we implemented a ten-fold cross-validation approach to assess the classifying 299 ability of each of these genes using various machine learning classifiers include ExtraTrees, Naive 300
Bayes, KNN, Random forest, Logistic Regression (LR), and SVC-RBF as represented in Table S3  301 (Supplementary Information File 1). Five out of 10 genes include FCN3, CLEC1B, CLEC4M, PRC1, 302
and PBK are the best performers to distinguish HCC and normal samples with sensitivity, specificity 303 accuracy more than 90%, MCC and AUROC greater than 0.8 and 0.95, respectively as shown in Table  304 S3 (Supplementary Information File 1). 305
3.3
Multiple-Genes based Prediction Models and their Validation on External Validation 306
Datasets 307
Next, we sought to identify a minimum predictive gene signature that can classify HCC and non-308 tumorous samples with high precision. Thus, prediction models developed for each gene from the top 309 five genes using different machine learning algorithms like ETREES, Naive Bayes, KNN, Random 310
Forest, LR, and SVC-RBF. Prediction performance of these models was evaluated by using ten-fold 311 cross-validation (CV) on the training dataset. Although models based on each of five genes can 312 distinguish HCC and normal samples of training datasets with high precision, i.e. more than 90% 313 sensitivity and specificity. To reduce bias through overfitting and to assure their independence on the 314 testing set, their performance is further evaluated on three external validation datasets. There was a 315 substantial decrease in specificity on these validation datasets (Supplementary Information File 1, 316 Table S4 ). Therefore, we further developed several models on combining these five genes in various 317 combinations using different machine learning algorithms. 318
The Diagnostic Performance of Five-genes HCC Biomarker-based Models in Identifying 319
HCC 320
At first all the five genes are combined and subsequently, prediction models developed using 321 different algorithms, i.e. ETREES, Naive Bayes, KNN, Random Forest, LR, and SVC-RBF. These 322 models discriminate HCC and normal samples with sensitivity, specificity in a range of 93-97%, an 323 accuracy 95-98%, along with AUROC 0.98-0.99 of training dataset as well as three different cross-324 platform datasets (shown in Table 3 ). 325 326 327 
.1.2 Four-genes and Three-genes HCC Biomarker-based Models 336
To reduce the number of genes from the Five-genes HCC biomarker without compromising the 337 classification performance; we developed several models using the different combination of these five 338 genes, which include Three-genes and Four-genes HCC biomarker sets. non-tumor samples with good prediction power, i.e. sensitivity and specificity in the range of 93-97% 345
with AUROC in the range of 0.97-0.99 on both training and three independent validation data sets as 346
shown in Table S5 ( Supplementary Information File 1) . 347
Prediction models built on Four-Genes HCC Biomarker-B almost performed in similar manner 348
with an accuracy more than 97% and AUROC in the range of 0.97-0.99 on training and two 349 independent validation data sets. While, there is a marginal decrease in the performance on third 350 independent validation dataset, i.e. specificity decreased for Random forest and SVC model in the 351 range 82-92% as shown in Supplementary Table S6 . 352  3.3.1.2 
.2 The Diagnostic Performance of Three-genes HCC Biomarker based Models for 353
Identification of HCC samples 354
To further reduces the genes from HCC biomarker panel, two "Three-genes Biomarker" sets 355 designed as Three-genes HCC Biomarker-A contains FCN3, CLEC1B, PRC1 and second Three-genes 356 HCC Biomarker-B includes FCN3, CLEC4M, PRC1. Models based on "Three-genes HCC Biomarker-357
A" categorize HCC and non-tumor samples very efficiently, i.e. accuracy 95-98% with AUROC in the 358 range of 0.96-0.99 on training as well as independent validation data sets as shown in Table 4 . The 359 expression pattern of these three-genes among samples of training dataset and three external validation 360 datasets depicted in Figure 3 . 361 362 363 Most of the models based on "Three-genes HCC Biomarker-B" performed in similar range in 378 classifying samples with a marginal decrease in performance, i.e. sensitivity and specificity in range 379 of 91-97% with an accuracy of 92-98% on training and validation data sets as shown in Table S7  380 (Supplementary Information File 1). 381
Prediction Model based on the Gene Expression of already identified protein-based 382 biomarker for diagnosis of HCC 383
To understand the importance of our "Three-genes HCC biomarker", we also developed prediction 384 models using gene expression of already identified proteins biomarkers, i.e. AFP+GPC3 and 385 AFP+GPC3+KRT19 (CK19) [49] . As we do not have their protein expression for these patients' 386
samples, hence we employed only their gene expression values. Models based on AFP+GPC3+KRT19 387 classified HCC and normal samples of training dataset with an accuracy 67-75%. While, this model 388 attained accuracy of 69-77%, 55-87% and 50-74% on external validation dataset1, dataset2 and 389 dataset3, respectively as shown in Table S8 ( Supplementary Information File 1) . Further, the prediction 390 models based on AFP+GPC3 have improved performance on training dataset with an accuracy of 70-391
77%, but lower performance on all three validation datasets as given in Table S9 (Supplementary 392
Information File 1). 393
Prognostic Potential of the "Three-genes HCC biomarker" in the Survival of HCC Patients 394
To examine the prognostic potential of "Three-genes HCC Biomarker-A", univariate survival 395 analysis was performed on TCGA and GSE14520 cohorts. The samples were partitioned into low-risk 396
and high-risk groups. Interestingly, all three genes of "Three-genes HCC Biomarker-A" are 397 significantly associated with the survival of HCC. For instance, higher expression (greater than mean) 398 of CLEC1B and FCN3 significantly associated with good outcome of the patients, i.e. OS, DSS, DFS 399 and PFS; while the overexpression of PRC1 is significantly associated with poor survival include DSS, 400 DFS or RFS and PFS of HCC patients for TCGA dataset as shown in Figure 4 . In GSE14520 dataset, 401
higher expression of PRC1 is significantly associated with the poor outcome of patients i.e. OS and 402 DFS or RFS, while the higher expression of FCN3 significantly associated with the better outcome of 403 HCC patients as depicted in Figure 5 . Complete results of survival analysis with HR (Hazard Ratio), 404
with 95% CI and p-value are represented in Table S10 
3.6
Web server 413
To facilitates the scientific community working in the area of the liver cancer research, we 414 developed HCCPred (Prediction Server for Hepatocellular Carcinoma). In HCCPred, we execute 415 mainly two modules; Prediction Module and Analysis Module based on robust Five-genes, Four-genes 416
and Three-genes HCC biomarkers and 26 Core genes of HCC identified in the present study for the 417 prediction and analysis of samples from the RNA-expression data. The Prediction Module permits the 418 users to predict the disease status, i.e. cancerous or normal using RNA expression values of a subset of 419 genes using in-silico prediction models based on robust Five-genes, Four-genes and Three-genes HCC 420
biomarkers identified in the present study. Here, the user required to submit RMA (for Affymetrix), 421
A Taken together, we have established robust three-gene HCC diagnostic biomarker with reasonable 469 performance, possess both diagnostic and prognostic potential; and a meta-data integration pipeline for 470 identification of robust biomarker using machine learning technique, which can work across the 471 different platforms. Further, this pipeline can be used for the analysis of any other cancer type. 472
Although more and more research is under the development of novel biomarkers, further work will be 473 required to implement the clinical utilization of identified biomarker to meet real-world demand. We 474 are anticipating that the identifying novel cost-efficient biomarker using predictive technology for 475 detection of HCC will be promising. 476
Conclusions 477
This study identified and validated a highly accurate Three-genes HCC biomarker for 478 discriminating HCC and non-tumorous tissue samples, also possess a significant prognostic potential 479 that may facilitate more accurate early diagnosis and risk stratification upon validation in prospective 480 clinical trials. Moreover, the product of FCN3 gene is released in the serum and bile, thus this may 481 serve as non-invasive diagnostic biomarkers. Additionally, the uniform overexpression-pattern of 482 PRC1 among numerous HCC samples suggest it as a novel potential therapeutic target. 483 
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